Ketamine and Esketamine in Psychiatric Practice: What PMHNPs Need to Know in 2026

The Ketamine Landscape in 2026

In the context of ketamine esketamine PMHNP, The use of ketamine and its derivatives in psychiatric practice has evolved significantly. Esketamine (Spravato) remains the only FDA-approved ketamine formulation for psychiatric indications, currently approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation. IV racemic ketamine continues to be used off-label in specialized clinics, while oral and sublingual ketamine formulations exist in a regulatory gray area.

For PMHNPs, understanding this landscape is essential because patients are increasingly asking about ketamine therapy, and some are already receiving it from other providers. Whether or not you plan to administer ketamine directly, you need to know how it interacts with your patients’ existing medication regimens, what monitoring is required, and when referral to a ketamine provider is appropriate.

The regulatory environment continues to evolve. Several states have clarified PMHNP scope of practice regarding ketamine administration, and the DEA has increased scrutiny of telehealth-based ketamine prescribing. Staying current on both the clinical evidence and regulatory requirements is crucial for safe, informed practice.

Esketamine (Spravato): REMS Requirements and Clinical Protocol

Esketamine is administered as a nasal spray under the Spravato REMS program, which requires administration in a certified healthcare setting with a two-hour post-dose observation period. PMHNPs can become certified Spravato prescribers by enrolling in the REMS program, though some states and practice settings may have additional requirements.

The standard dosing protocol begins with 56mg intranasally twice weekly for four weeks (induction phase), then transitions to once weekly for four weeks, and finally to once weekly or every two weeks for maintenance. The prescriber must be present during each administration session to assess the patient’s clinical status and manage any adverse effects.

During the two-hour observation period, monitor blood pressure at 40 minutes and again before discharge. The most common side effects are dissociation, dizziness, nausea, sedation, and transient blood pressure elevation. Patients cannot drive or operate machinery for the remainder of the day after treatment. Document vital signs, side effects, dissociation severity, and clinical response at each visit.

IV Ketamine: Off-Label Use and Clinical Considerations

IV racemic ketamine for depression is used off-label and is not subject to the Spravato REMS. However, it requires appropriate clinical infrastructure including IV administration capability, monitoring equipment, and emergency supplies. Many PMHNPs work in or refer to dedicated ketamine clinics that provide this service.

Typical IV ketamine protocols use 0.5mg/kg infused over 40 minutes, administered twice weekly for 2-3 weeks as an initial course. Response rates in clinical trials range from 50-70% for treatment-resistant depression, with onset of antidepressant effect often within hours to days rather than the weeks required for traditional antidepressants.

The evidence base for IV ketamine is robust but largely consists of short-term trials. Long-term maintenance protocols vary widely between clinics, and the optimal frequency and duration of maintenance infusions remain active areas of research. PMHNPs referring patients for IV ketamine should discuss maintenance expectations with the treating clinic and coordinate ongoing medication management.

Oral and Sublingual Ketamine: The Regulatory Gray Area

Oral and sublingual ketamine formulations prescribed through compounding pharmacies exist in a complex regulatory space. While prescribing compounded ketamine is technically legal in most states, the FDA has issued warning letters to several compounding pharmacies and telehealth companies marketing ketamine products without adequate clinical oversight.

The bioavailability of oral ketamine is approximately 20-25%, significantly lower than IV or intranasal routes. Sublingual formulations achieve approximately 30% bioavailability. These lower bioavailability profiles mean higher doses are needed, which affects both efficacy and side effect profiles. Additionally, at-home use without clinical observation raises safety concerns that the Spravato REMS was specifically designed to address.

For PMHNPs, the safest approach is to prescribe esketamine through the REMS program or refer to established IV ketamine clinics. If patients are already receiving compounded oral ketamine from another provider, document this in your treatment notes, discuss the regulatory and safety considerations, and coordinate care with the prescribing provider.

Patient Selection and Integration with Existing Treatment

Ketamine-based treatments are most appropriate for patients who meet criteria for treatment-resistant depression, defined as inadequate response to at least two adequate antidepressant trials. Esketamine specifically requires documented failure of at least two antidepressants for the TRD indication, or current major depressive episode with acute suicidal ideation for the MDSI indication.

Ketamine treatments work best as part of a comprehensive treatment plan that includes ongoing psychotherapy, medication optimization, and lifestyle interventions. Ketamine should not replace foundational treatments but rather augment them when standard approaches have been insufficient. Discuss realistic expectations with patients: ketamine provides rapid symptom relief but typically requires ongoing maintenance sessions to sustain benefits.

Screen carefully for contraindications including uncontrolled hypertension, aneurysmal vascular disease, history of psychosis, and active substance use disorders (particularly alcohol and PCP). Patients with a history of dissociative symptoms or PTSD may require modified protocols with lower initial doses and additional psychological support during sessions.

Frequently Asked Questions

This article is for educational purposes only and does not constitute medical advice. Ketamine prescribing involves controlled substance regulations and REMS requirements. Always follow your state scope of practice laws, DEA regulations, and current clinical guidelines. Consult with experienced ketamine providers before initiating treatment.